摘要
目的:观察咪唑斯汀对急性荨麻疹患者生活质量的影响。方法:将213例急性荨麻疹患者随机分为两组:咪唑斯汀组108例,西替利嗪组105例。两组患者均为10 mg口服,每日1次,连用14 d。于治疗前后记录荨麻疹活动度评分以及皮肤病生活质量评分表。结果:治疗1周后,咪唑斯汀组症状迅速改善,生活质量明显高于西替利嗪组,具有统计学意义。而在2周治疗后,患者的情况均得到改善,两组疗效的差异无统计学意义。结论:咪唑斯汀能在短时间内改善急性自发性荨麻疹患者症状,提高患者的生活质量评分。
Objective： To investigate the efficacy and safety treatment with mizolastine for acute urticaria, and assess the effect on quality of life. Methods： All of the patients with acute urticaria were randomly assigned into two groups： mizolastine treatment group （108 cases） and cetirizine treatment group （105 cases）. And the patients were taken mizolastine or cetirizine 10 mg daily for 14 days. The severity of acute urticaria in patients was rated according to UAS （uticaria activity score）. Dermatology life quality index （DLQI） questionnaire scores were used and then statistical analysis was made. Results： After 7 days, there were significant differences in the UAS and DLQI among the two groups. The UAS and DLQI scores significantly improved in the mizolastine group. No severe adverse reactions were observed. Conclusion： Mizolastine can not only decrease UAS scores but also improve the DLQI in patients with acute urticaria.
出处
《临床皮肤科杂志》
CAS
CSCD
北大核心
2012年第6期349-351,共3页
Journal of Clinical Dermatology
